US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · Diabetic Macular Edema · Non-infectious Uveitis Affecting the Posterior Segment of the Eye · ANIP
ANI PHARMACEUTICALS
ANI PHARMACEUTICALS INC
ANI PHARMACEUTICALS drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
500 Alexander Park, Princeton, New Jersey 08540, US HQ
678 Employees
Public company Type
ANIP · NYSE Ticker
Company details
- Status
- Public
- HQ
- 500 Alexander Park, Princeton, New Jersey 08540, US
- Employees
- 678
- Programs
- 11
- Drugs
- 7
- Patents
- 7
ANI PHARMACEUTICALS pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ANI PHARMACEUTICALS drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to ANI PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to ANI PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP3 subtype.
- Target
- Prostaglandin E2 receptor EP3 subtype
- Mechanism
- Prostanoid EP3 receptor agonist
-
US regulatory status: approved.